HPV-16 E2 physical status and molecular evolution in vivo in cervical carcinomas.

Kahla S, Kochbati L, Chanoufi MB, Maalej M, Oueslati R.
Int J Biol Markers. 2013 Oct 28:0. doi: 10.5301/jbm.5000051. [Epub ahead of print]

Impact of sampling origin on molecular detection of high-risk human papillomavirus and oncogene expression.
Kahla S, Achour M, Oueslati S, Kochbati L, Chanoufi MB, Maalej M, Oueslati R.
Eur J Gynaecol Oncol. 2012;33(2):187-92.

Correlation between ebv co-infection and HPV16 genome integrity in Tunisian cervical cancer patients.
Kahla S, Oueslati S, Achour M, Kochbati L, Chanoufi MB, Maalej M, Oueslati R.
Braz J Microbiol. 2012 Apr;43(2):744-53. doi: 10.1590/S1517-83822012000200039. Epub 2012 Jun 1.

Clear cell carcinoma of the uterus.
Hentati D, Belghith B, Kochbati L, Driss M, Maalej M.
Tunis Med. 2010 Apr;88(4):230-3.

Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
Achour M, Zeghal D, Kochbati L, Kahla S, Zouari F, Maâlej M, Oueslati R.
J Immunoassay Immunochem. 2009;30(1):82-96. doi: 10.1080/15321810802569543.